217189-04-3

Usage

Uses

Used in Pharmaceutical Research and Development:
(4-PYRID-3-YLPHENYL)METHANOL is used as a key intermediate in the synthesis of pharmaceuticals for its unique reactivity and structural properties, contributing to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic chemistry, (4-PYRID-3-YLPHENYL)METHANOL is used as a building block for the creation of various organic compounds, leveraging its structural features to form complex molecules with specific functionalities.
Used in Drug Discovery:
(4-PYRID-3-YLPHENYL)METHANOL is utilized as a starting material in drug discovery processes, where its unique structure may lead to the identification of novel therapeutic agents with improved efficacy and selectivity.
Used in Material Science:
In material science, (4-PYRID-3-YLPHENYL)METHANOL may be employed in the development of new materials with specific properties, such as those with enhanced electronic or optical characteristics, by incorporating its molecular structure into the material's composition.

InChI:InChI=1/C12H11NO/c14-9-10-3-5-11(6-4-10)12-2-1-7-13-8-12/h1-8,14H,9H2

Upstream product

• 619-42-1 4-methoxycarbonylphenyl bromide 
• 329214-79-1 3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1692-25-7 3-pyridylboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 

Relevant academic research and scientific papers

PYRROLIDINE GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans

This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).